63 related articles for article (PubMed ID: 22544017)
1. Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.
Ayan-Oshodi M; Wondmagegnehu ET; Lowe SL; Kryzhanovskaya L; Walker DJ; Kinon BJ
J Clin Psychopharmacol; 2012 Jun; 32(3):408-11. PubMed ID: 22544017
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
3. Comment on: "Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate" by Ayan-Oshodi et al (J Clin Psychopharmacol 2012;32[3]:408-411).
Seeman P
J Clin Psychopharmacol; 2013 Apr; 33(2):280. PubMed ID: 23422392
[No Abstract] [Full Text] [Related]
4. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
Downing AM; Kinon BJ; Millen BA; Zhang L; Liu L; Morozova MA; Brenner R; Rayle TJ; Nisenbaum L; Zhao F; Gomez JC
BMC Psychiatry; 2014 Dec; 14():351. PubMed ID: 25539791
[TBL] [Abstract][Full Text] [Related]
5. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Lowe S; Dean R; Ackermann B; Jackson K; Natanegara F; Anderson S; Eckstein J; Yuen E; Ayan-Oshodi M; Ho M; McKinzie D; Perry K; Svensson K
Psychopharmacology (Berl); 2012 Feb; 219(4):959-70. PubMed ID: 21847569
[TBL] [Abstract][Full Text] [Related]
6. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
7. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mehta MA; Schmechtig A; Kotoula V; McColm J; Jackson K; Brittain C; Tauscher-Wisniewski S; Kinon BJ; Morrison PD; Pollak T; Mant T; Williams SCR; Schwarz AJ
Psychopharmacology (Berl); 2018 Jul; 235(7):1875-1886. PubMed ID: 29564482
[TBL] [Abstract][Full Text] [Related]
8. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia.
Kinon BJ; Gómez JC
Neuropharmacology; 2013 Mar; 66():82-6. PubMed ID: 22722029
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
10. [The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Mosolov SN; Smulevich AB; Neznanov NG; Tochilov VA; Andreev BV; Avedisova AS; Bardenshteĭn LM; Gurovich IIa; Reznik AM; Zharkova NB; Martenyi F
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):16-23. PubMed ID: 20639852
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.
Liu W; Downing AC; Munsie LM; Chen P; Reed MR; Ruble CL; Landschulz KT; Kinon BJ; Nisenbaum LK
Pharmacogenomics J; 2012 Jun; 12(3):246-54. PubMed ID: 21173788
[TBL] [Abstract][Full Text] [Related]
12. A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia.
Stauffer VL; Baygani SK; Kinon BJ; Krikke-Workel JO
J Clin Psychopharmacol; 2014 Oct; 34(5):552-8. PubMed ID: 25006819
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
14. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.
Fountain NB; Krauss G; Isojarvi J; Dilley D; Doty P; Rudd GD
Epilepsia; 2013 Jan; 54(1):58-65. PubMed ID: 22708895
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
20. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Fell MJ; McKinzie DL; Monn JA; Svensson KA
Neuropharmacology; 2012 Mar; 62(3):1473-83. PubMed ID: 21704048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
